Guillain ‐Barré syndrome following COVID‐19 vaccination: An updated systematic review of cases

Prisma Flow diagram of the studies included in the systematic review;GBS following COVID-19 vaccination. Key Clinical MessageGuillain-Barr é syndrome (GBS) is a rare but possible complication that may occur after COVID-19 vaccination. In this systematic review, we found that GBS presented in patients with an average age of 58. The average time for symptoms to appear was 14.4 days. Health care providers should be aware of this potent ial complication.AbstractMost instances of Guillain-Barr é syndrome (GBS) are caused by immunological stimulation and are discovered after vaccinations for tetanus toxoid, oral polio, and swine influenza. In this systematic study, we investigated at GBS cases that were reported after receiving the COVID-19 vaccination. Based on PRISMA guidelines, we sear ched five databases (PubMed, Google Scholar, Ovid, Web of Science, and Scopus databases) for studies on COVID-19 vaccination and GBS on August 7, 2021. To conduct our analysis, we divided the GBS variants into two groups, acute inflammatory demyelinating polyneuropathy and non-acute inflammatory dem yelinating polyneuropathy (AIDP and non-AIDP), and compared the two groups with mEGOS and other clinical presentation In this systematic review, 29 cases were included in 14 studies. Ten cases belonged to the AIDP variant, 17 were non-AIDP (one case had the MFS variant, one AMAN variant, and 15 case s had the BFP variant), and the two remaining cases were not mentioned. Following COVID-19 vaccinati...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research